The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Eli Lilly (LLY) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Eli Lilly is a member of our Medical group, which includes 1025 different companie ...

The U.S. Food and Drug Administration (FDA) has announced that the supply shortages of Eli Lilly's (LLY, Financial) popular weight-loss and diabetes medications, Zepbound and Mounjaro, have been resolved. This resolution may impact the market presence of generic versions that had become popular due to previous shortages. The initial shortage led the FDA to permit pharmacies to sell less-tested generic versions. Eli Lilly has been increasing investments to boost medication supply, including constructing a ne ...

The U.S. Food and Drug Administration (FDA) recently announced that the shortage of Eli Lilly's weight loss medications, Mounjaro and Zepbound, has been resolved. While these drugs, which contain tirzepatide, are now more readily available, patients and prescribers might still face occasional local shortages as they move through the supply chain.Mounjaro, which is primarily used for diabetes treatment, and Zepbound, used for weight control, had been listed on the FDA's shortage list since late 2022 and Apri ...

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024.Eli Lilly will spend $4.5 billion to build a center aimed at finding better ways to manufacture its medicines. The facility, called the Lilly Medicine Foundry, will house development of new manufacturing methods with an eye toward efficiency. It's a strategy that's already paying off with Lilly's obesity and weight loss drugs Mounjaro and Zepbound, and Lilly wants it to propel the rest of i ...

Indiana facility will combine research, manufacturing and the latest technology to innovate new production methods and scale global access to clinical supply for Lilly's growing pipeline Opening in late 2027, the facility will increase Lilly's total capital commitment in the United States to more than $23 billion since 2020 INDIANAPOLIS, Oct. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced man ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this drugmaker have returned -8.6% over the past month versus the Zacks S&P 500 composite's +2.1% change. The Zacks Large Cap Pharmaceuticals industry, to which Lilly belongs, has lost 5.5% over this period. Now the key question is: Where could the stock be headed in the near term?Although me ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for a free trial to Growth Stock Forum.With all the focus on Eli Lilly's (NYSE: LLY ) obesity business, the rec ...

Eli Lilly could keep growing for years without changing its strategy.Eli Lilly (LLY -3.47%) is already a top pharmaceutical stock, and there are no signs that it's slowing down. With its dramatically successful medicines for type 2 diabetes and weight loss still near the start of their global market penetration, and with an array of follow-on drugs in development right now, the party for shareholders could continue for years and years.That's just one of several arguments for why it's worth investing $1,000 ...

These two players are set on finding the next big therapeutic modality.Eli Lilly (LLY -3.47%) and Novo Nordisk (NVO -2.85%) are archrivals thanks to their dueling drugs for weight loss, Zepbound and Wegovy, as well as their competing therapies for type 2 diabetes, Mounjaro and Ozempic.But dominance in a pharmaceutical segment never lasts forever. Over a long-enough period, new entrants can copy the winners' products and produce generic versions for a fraction of the cost. Therefore, ongoing innovation is th ...

It's hard to bet against this company right now.The group of $1 trillion market cap stocks is tiny, and pharmaceutical giant Eli Lilly (LLY -3.47%) isn't a member yet, though it is within striking distance at about $820 billion.However, the drugmaker's prospects look so strong that not only should it soon join the $1 trillion club, but it could even be a member of the more exclusive $2 trillion club by 2030. Here's why.The tirzepatide tailwindWhat's considered "solid" growth in revenue for a corporation? Th ...